TrialScience translational medicine2013

Low-dose interleukin-2 therapy restores regulatory T cell homeostasis in patients with chronic graft-versus-host disease.

Ken-ichi Matsuoka et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.